Home / Home

Biliary Tract Cancer Research

Biliary tract cancer research focuses on chemoimmunotherapy combinations, FGFR2 and IDH1-directed targeted therapy, and molecular profiling of cholangiocarcinoma subtypes.

Our Biliary Tract Cancer Analysis

  • November 2, 2026Clinical Cancer ResearchPhase II, single-arm, open-label (NCT02703714)

    Pembrolizumab Plus GM-CSF Misses Its Response-Rate Target in Advanced Biliary Cancer, Though Well Tolerated, in a Single-Center Phase II Trial

    In an open-label, single-center, single-arm phase II trial at UCSF, 42 previously treated patients with advanced biliary cancer received pembrolizumab plus GM-CSF. The confirmed objective response rate was 12% (5 of 42; 95% CI: 0.04, 0.26), below the prespecified 20% threshold for meaningful efficacy. Median progression-free survival was 2.1 months (95% CI: 1.8, 4.2) and median overall survival was 13.1 months (95% CI: 8.1, 19.1).

  • July 13, 2026Journal of Clinical OncologyACT-GI, randomized phase II, NCT05772546

    Avatrombopag Meets Its Primary Endpoint in 70% vs 17% of Patients With Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers, in a Small Trial Stopped Early at Interim Analysis: The Phase II ACT-GI Trial

    ACT-GI was a multicenter, randomized, double-blind, placebo-controlled, investigator-initiated phase II trial at four US sites. Forty-seven adults receiving chemotherapy for gastrointestinal cancers with persistent chemotherapy-induced thrombocytopenia (platelet count ≤85 × 10⁹/L on day 1 of a scheduled cycle despite adequate recovery time) were assigned 1:1 to oral avatrombopag (n = 23) or placebo (n = 24). The primary endpoint, a composite of platelet recovery to ≥100 × 10⁹/L, completing one on-study chemotherapy cycle without thrombocytopenia-related dose reduction or delay, and ≥100 × 10⁹/L at the start of the next cycle, was met by 16 of 23 patients (70%; 95% CI, 47 to 87) with avatrombopag vs 4 of 24 (17%; 95% CI, 5 to 37) with placebo (Z = 3.67, P < .001).

  • October 20, 2026Journal of Clinical OncologyASCOT (JCOG1202; multicenter, open-label, randomized phase 3), UMIN000011688

    Adjuvant S-1 Sustains Its Overall Survival Benefit at Five Years in Resected Biliary Tract Cancer: Final Analysis of the Phase 3 ASCOT (JCOG1202) Trial

    ASCOT (JCOG1202) randomly assigned 440 patients at 38 Japanese institutions, after curative-intent resection of biliary tract cancer (BTC), to observation (n = 222) or adjuvant S-1 (n = 218). In this final prespecified analysis, 5 years after the completion of accrual, median overall survival (OS) was 8.2 years with S-1 versus 5.9 years with observation; 5-year OS was 64% versus 52% (HR 0.72; 95% CI, 0.55 to 0.95; one-sided P = .01).

  • September 22, 2026Nature MedicinePATHFINDER 2 (NCT05155605)

    Multi-Cancer Blood Test Reaches 60% Positive Predictive Value and 99.6% Specificity in Largest Prospective Screening Study to Date

    PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.

  • September 22, 2026Nature MedicineHERBOT / KCSG-HB23-05 (NCT05749900)

    First-Line Trastuzumab Add-On Reaches 55% Response Rate in HER2-Positive Biliary Tract Cancer

    A single-arm, phase 1b/2 trial (HERBOT) tested adding the HER2-targeted antibody trastuzumab to first-line nivolumab plus gemcitabine-cisplatin chemoimmunotherapy in 40 patients with HER2-positive, previously untreated, unresectable or metastatic biliary tract cancer — the first prospective study to introduce HER2-directed therapy immediately rather than reserving it for a later treatment line.

  • September 15, 2026Clinical Cancer ResearchNCI/ETCTN 10476 (NCT04941287)

    Adding a CD27 Agonist to Checkpoint Blockade Fails to Improve Response in Biliary Tract Cancer

    A randomized phase II trial testing whether the CD27 costimulatory agonist varlilumab, combined with atezolizumab and the MEK inhibitor cobimetinib, could rescue checkpoint-inhibitor activity in previously treated, unresectable biliary tract cancer closed early for futility after a preplanned interim analysis.

  • August 20, 2026JAMA Oncology

    Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

    A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

  • July 9, 2026JAMA OncologyTOPAZ-1 (NCT03875235)

    Durvalumab Plus Chemotherapy Sustains Survival Benefit at 4 Years in Advanced Biliary Tract Cancer: Final Analysis of the Phase 3 TOPAZ-1 Trial

    Final post hoc analysis of the global, double-blind, placebo-controlled phase 3 TOPAZ-1 trial (685 patients randomized 1:1) reporting the longest published follow-up — approximately 4 years — of an immunotherapy-plus-chemotherapy regimen in first-line advanced biliary tract cancer (aBTC)

Related topics: Checkpoint Inhibitor Combinations · Fixed-Duration and De-escalated Therapy · HER2-Directed Therapy · Immunotherapy Plus Chemotherapy